---
title: "Capital Cell Review 2026: Biotech Crowdfunding Fees, Exits and Investor Returns"
url: https://altstreet.investments/platforms/reviews/capital-cell
kind: platform-review
updated: 2026-11-10
description: "Capital Cell review 2026: fees, exits and investor returns at the EU-licensed biotech crowdfunding platform: 156 rounds since 2016, 4 exits at 3 companies and 14 write-offs by its own labels, 3.19x reported value against 0.51 cash returned (November 2022), and an 8% share of investor profit."
publisher: AltStreet (https://altstreet.investments)
license: Public factual pages may be read, quoted and cited with attribution and a link. Bulk redistribution is not permitted.
---

# Capital Cell Review 2026: Biotech Crowdfunding Fees, Exits and Investor Returns

Capital Cell is a Barcelona equity crowdfunding platform for early-stage biotech and medical companies, licensed by Spain's CNMV under the EU crowdfunding regulation and open across 26 other EU states from about EUR 500 a ticket. Its public track record lists 156 rounds since April 2016 (EUR 157.1 million of round size, including lead investors): 138 'In business', 14 'Write-off' and 4 'Exit' at three companies, with exit proceeds not published. Its own analysis of the 2015 to 2022 portfolio put reported value at 3.19x invested capital on paper, 1.14x without its three best investments, and cash returned as of November 2022 at 0.51.

AltStreet score: 39.5 (C-), scored November 10, 2026. Method: https://altstreet.investments/platforms

| Field | Value |
| --- | --- |
| Platform | Capital Cell |
| What it is | EU Equity Crowdfunding Platform (Life Sciences) |
| Asset class | Biotech / Early-Stage Life Science Equity |
| Website | capitalcell.com |
| Review first published | November 9, 2026 |
| Last updated | November 10, 2026 |
| AltStreet relationship | None: no affiliate, sponsorship or partnership |

## The short version

Capital Cell, founded in Barcelona in 2015 by biologist Daniel Oliver Uriel, lets individuals buy into early-stage life-science companies (medical devices, biotech, new drugs, digital health, diagnostics) alongside a lead investor who sets the price. It is run by PFP CAPITAL CELL, S.L., authorized by Spain's CNMV as European crowdfunding service provider no. 12 since November 10, 2023, and notified to offer its service in the 26 other EU states; tickets start around EUR 500, money waits with a payment institution (MarketPay) until the company's capital increase is registered, and crowd investors usually hold through a Dutch STAK foundation. The platform publishes more of its record than most: every round since 2017 with a status label, a register of related-party investments and an analysis that states its own realized return. That record is young and lopsided: 156 rounds, 14 labelled written off and 4 labelled exits at three companies (Vytrus Biotech's market listing, Goodgut's sale to Hipra, and two Bionure rounds; Bionure merged with Iproteos in 2020 to form Accure Therapeutics), with no published figure for what investors received from any exit. Capital Cell's analysis of its 2015 to 2022 portfolio, a different cohort from today's track-record table, reported a portfolio value of 3.19x invested capital, 1.14x without its three best investments, and cash returned of 0.51 as of November 2022. Published fee rates differ by page: the company's success fee is 8% in the promoter conditions and terms but 7% in the investor FAQ, and investors holding through the STAK pay 8% of any profit at exit and 8% on early transfers. One register discrepancy needs an answer: the CNMV still lists the operator's sole owner as Capital Cell Ltd, a UK company that Companies House shows dissolved in June 2025 after a members' voluntary liquidation.

- **156 rounds** The track record lists 156 rounds from April 2016 to October 2026, EUR 157.1 million of round size (which includes lead and co-investors, not only crowd money). By year: 1 (2016), 5 (2017), 5, 14, 14, 16, 19, 19, 21, 25 and 17 (2026 to October). The home page says '175 Closed Rounds' and '168M€ Total Invested'; the difference is not explained (Capital Cell UK rounds, for example, are not on the list).
- **4 exits, 14 write-offs** Labelled exits: four rounds at three companies. Vytrus Biotech (October 2017 round; listed on Spain's BME Growth market in 2022), Bionure (March 2017, EUR 477,000, and July 2019; Bionure merged with Iproteos in 2020 to form Accure Therapeutics) and Goodgut (2019; sold to Hipra). Labelled write-offs: 14 rounds, EUR 8.0 million of round size, including Frontwave Imaging twice, RUTI Immune (EUR 1.6 million), HCS Pharma and Exheus. Of the 39 rounds from 2016 to 2020, 8 are written off, 4 are labelled exit and 27 are still 'In business'. Exit proceeds are not published.
- **3.19x reported, 0.51 cash** Capital Cell's analysis of its 2015 to 2022 portfolio (78 companies, a different cohort from today's track-record table): reported value 'X3.19' of invested capital, mostly paper gains from later rounds; 'if we remove the 3 investments with the greatest revaluation, the portfolio return goes from X3.19 to only X1.14' (Spanish edition); and 'the cash return as of November 2022 is only 0.51'. The home page now shows '2,7x' portfolio value, not updated with a cash figure.
- **8% or 7%** Company side: EUR 1,500 at campaign activation and a cash success fee of 8% (EUR 10,000 minimum) in the promoter conditions, terms and company FAQ; the investor FAQ says 7%. Investor side: through the STAK, 8% of profit at exit and 8% on transfers before exit; the how-to-invest page calls it 'an 8% carried interest'. The conditions apply 'unless expressly agreed', so check the terms of each round.
- **CNMV no. 12** PFP CAPITAL CELL, S.L. (NIF B65998288) is an authorized crowdfunding service provider under Regulation (EU) 2020/1503 since November 10, 2023, with cross-border notifications for 26 EU states. A register discrepancy: the CNMV's partner view still shows 'CAPITAL CELL, LTD 100.00%', while Companies House records that UK company's members' voluntary liquidation (resolution July 2024) and dissolution on June 17, 2025. No sanction or warning was located.
- **EUR 639,447** Related-party investments disclosed under the EU regulation: 106 entries in 70 projects by partners (EUR 364,765), other related parties (EUR 225,030) and employees (EUR 49,651), including in companies later written off.

Data note: Round counts, sizes and status labels are Capital Cell's track-record pages as captured November 9, 2026 (recounted November 10); round size includes lead investors. Return multiples are Capital Cell's own analysis (paper values from later round prices). Write-offs and exits are not checked against company registries. Amounts in euros.


## Key figures

| Figure | What it is | Context |
| --- | --- | --- |
| 156 | Rounds on the track record | April 2016 to October 2026; EUR 157.1M round size including leads. |
| 4 / 14 | Exits / write-offs | Platform labels; the 4 exits are at 3 companies; proceeds not published. |
| 3.19x / 0.51 | Reported value / cash returned, November 2022 | Capital Cell's 2015 to 2022 portfolio; 1.14x on paper without the top three. |
| 8% / 8% | Company success fee / investor share of profit | Investor FAQ says 7% for the company; investors also pay 8% on transfers before exit. |


## Verdict

Capital Cell is a regulated, specialist venture platform that shows more of its record than most: every round with a status, a related-party ledger, and its own report that the 2015 to 2022 portfolio was valued at 3.19x on paper while cash returned stood at 0.51 in November 2022. The record is young, with 4 exit labels at 3 companies in ten years and 14 write-offs, and the realized proceeds are not published. Fees take 8% of investor profit at exit, and the published company rate is 8% in the terms but 7% in the investor FAQ. Before investing, read the round's own fee terms, ask who owns the operator given the register discrepancy over its dissolved UK parent, and treat the 2.7x on the home page as paper value.

**Best for**

- EU investors building a long-horizon, diversified set of life-science startup stakes
- Investors who want to follow lead investors' pricing

**Look elsewhere if**

- You need liquidity or income
- You are a US retail investor
- You expect realized returns soon

**Strengths**

- CNMV-authorized EU crowdfunding provider, passported to 26 states
- Full public round list with write-off and exit labels
- Related-party investment ledger and audited operator accounts (behind login)
- The platform's own cash-return figure published alongside paper multiples
- Lead investor sets the price in every round; all-or-nothing escrow at a payment institution

**Limitations**

- 4 exit labels at 3 companies since 2016, proceeds not published
- 14 write-offs by the platform's labels, not registry-checked
- 8% of profit at exit and 8% on early transfers; published company fee rates conflict (8% vs 7%)
- Register discrepancy: CNMV still lists a UK owner dissolved in 2025
- Headline figures (175 rounds, EUR 168M, 2.7x) do not reconcile with the 156-round track record


## Who it fits

| Investor | Fit | Why |
| --- | --- | --- |
| EU investors who want a spread of small, long-term biotech and medtech stakes alongside lead investors | well-suited |  |
| US investors | poor-fit |  |
| Investors who need liquidity or income | poor-fit |  |


## Questions

**What is Capital Cell?**

A Barcelona-based equity crowdfunding platform for early-stage life-science companies, run by PFP CAPITAL CELL, S.L. and authorized by Spain's CNMV as a European crowdfunding service provider (no. 12). Investors buy shares, usually through a Dutch STAK, alongside a lead investor in each round.

**Is Capital Cell legit?**

It is licensed by the CNMV under the EU crowdfunding regulation, holds investor money at a payment institution until each round closes, publishes its full round list and a related-party ledger, and no sanction or dispute was located. The open question is ownership: the CNMV register still lists a UK parent that Companies House shows dissolved in 2025.

**What returns has Capital Cell delivered?**

Its analysis of the 2015 to 2022 portfolio reported a value of 3.19x invested capital on paper, 1.14x without its three best investments, and cash returned of 0.51 as of November 2022. The home page now shows 2.7x portfolio value. Four rounds at three companies are labelled exit (Vytrus Biotech, Goodgut and two Bionure rounds; Bionure merged into Accure Therapeutics in 2020); proceeds to investors are not published.

**How many Capital Cell investments have failed?**

Fourteen of 156 rounds are labelled 'Write-off' on the track record, EUR 8.0 million of round size; most rounds are from 2023 or later and too young to judge. Of the 39 rounds from 2016 to 2020, 8 are written off.

**What fees does Capital Cell charge?**

Published rates differ by page. Companies pay EUR 1,500 when the campaign page is activated and a cash success fee of 8% (EUR 10,000 minimum) per the promoter conditions and terms, though the investor FAQ says 7%. Investors holding through the STAK pay no annual fee, 8% of profit at exit (nothing if there is no profit) and 8% on transfers before an exit. The terms of each round govern.

**What is the minimum investment?**

Usually under EUR 1,000 and as low as about EUR 500. Under the EU regulation, non-sophisticated investors pass an entry knowledge test before full access, and investing more than the higher of EUR 1,000 or 5% of net worth in one project triggers a risk warning they must acknowledge.

**Can US investors use Capital Cell?**

Only as professional (accredited) investors, according to the FAQ; Capital Cell is not registered with the SEC. US persons should also check the tax treatment of a Dutch STAK certificate in a European company.

**Can I sell my Capital Cell investment?**

Through a bulletin board where registered users list shares and negotiate directly; direct shares are transferred before a notary, and STAK certificates carry an 8% transfer fee before exit.


## Evidence appendix

Platform website captured November 9, 2026.

Firecrawl captures of capitalcell.com (33 pages, all eight track-record pages parsed into 156 rounds, Spanish and English portfolio analyses, 2024 summary slides read as images); CNMV crowdfunding-provider register pages for provider no. 12; GLEIF; UK Companies House records for Capital Cell Ltd; web searches for sanctions and disputes. No account was opened.

**Highlights**

- Portfolio analysis: 'the cash return as of November 2022 is only 0.51'.
- Rendimiento de cartera: 'si eliminamos las 3 inversiones con mayor revalorización, el rendimiento de cartera pasa de X3,19 a únicamente X1,14'.
- Investor FAQs: 'Capital Cell takes a small commission on the capital it helps raise - 7% per project'.
- Conditions applicable to promoters: 'Cash Success Fee: An amount equivalent to 8% of the Commissionable Amount Raised, with a minimum of €10,000.'
- How to invest: 'An 8% carried interest at the time of divestment.'
- STAK page: 'A performance fee equivalent to 8% of the profit earned is charged.'
- CNMV partners: 'CAPITAL CELL, LTD 100.00%'.

**Primary source pages**

- capitalcell.com/en/ home, about, track record (8 pages), FAQs for investors and companies, STAK, MarketPay, secondary market, terms, legal notice, audited accounts, related parties (captured November 9, 2026)
- Capital Cell portfolio analysis 2015 to 2022 (English) and 'Rendimiento de cartera' (Spanish)
- CNMV register of crowdfunding service providers, PFP CAPITAL CELL, S.L. (no. 12): basic data, partners, board, services, cross-border notifications
- UK Companies House, Capital Cell Ltd (10173220): overview, officers, persons with significant control, filing history
- Capital Cell 2024 summary slides


## Related

- Full review (HTML): https://altstreet.investments/platforms/reviews/capital-cell
- Every platform review: https://altstreet.investments/platforms/reviews
- Methodology and scoring: https://altstreet.investments/platforms
- Category hub: https://altstreet.investments/categories/longevity-biotech

---

Source page: https://altstreet.investments/platforms/reviews/capital-cell
Machine index: https://altstreet.investments/llms.txt
AltStreet reads what platforms, funds and issuers file with the SEC and what they tell investors, and publishes the difference. Figures are as filed or as captured on the date stated; nothing here is investment advice.